Pragnya Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 12-07-2024
- Paid Up Capital ₹ 0.99 M
as on 12-07-2024
- Company Age 28 Year, 2 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 6.30 M
as on 12-07-2024
- Revenue %
(FY 2020)
- Profit 8.45%
(FY 2020)
- Ebitda -35.93%
(FY 2020)
- Net Worth -10.86%
(FY 2020)
- Total Assets -15.28%
(FY 2020)
About Pragnya Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.99 M.
The company has closed loans amounting to ₹6.30 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pragnyashree and Sanjaya Patra serve as directors at the Company.
- CIN/LLPIN
U24234OR1996PTC004671
- Company No.
004671
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Nov 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Pragnya Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaya Patra  | Managing Director | 08-Nov-1996 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pragnyashree | Director | 01-Nov-2021 | Current |
Financial Performance and Corporate Structure Insights of Pragnya Pharmaceuticals.
Pragnya Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 8.45% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pragnya Pharmaceuticals?
In 2020, Pragnya Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 13 May 2005 | ₹5.50 M | Satisfied |
Uco Bank Creation Date: 20 Dec 2003 | ₹0.80 M | Satisfied |
How Many Employees Work at Pragnya Pharmaceuticals?
Unlock and access historical data on people associated with Pragnya Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pragnya Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pragnya Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
